Aptevo's lead drug achieves second remission in early-stage blood cancer study

• In addition to the one previously announced, Aptevo Therapeutics (NASDAQ:APVO) says a second patient in cohort 6 has achieved complete remission (CR) in a Phase 1 trial evaluating its lead candidate APVO436 in patients with acute myeloid leukemia and myelodysplastic syndromes.
• Patient bone marrow blasts were 33% at screen, exhibited a rise to 46% after the first cycle of treatment, and subsequently dropped to 8% after the second cycle, and to 4% after the fourth cycle of treatment.
• The patient's platelet count and absolute neutrophil count met complete remission criteria.
• Also, data showed that one patient exhibited stable disease status, and six patients where the disease had progressed.
• https://seekingalpha.com/news/3633486-aptevos-lead-drug-achieves-second-remission-in-early-stage-blood-cancer-study